Skip to main content

Taggar

andningsvägar

cancer

diabetes

forskning & utveckling

hjärta/kärl

ledning

mage/tarm

neurovetenskap

AstraZeneca 239 cancer 187 forskning & utveckling 136 hjärta/kärl 128 diabetes 79 andningsvägar 57 mage/tarm 18 neurovetenskap 16 FDA 10 onkologi 9 astma 8 delårsrapport 8 forskning 7 infektion 7 seroquel 7 Observationsstudie 6 medimmune 6 forxiga 6 akut kranskärlssjudom 6 Tagrisso 5 vandetanib 5 influensavaccin 5 motavizumab 5 RWE 5 naloxegol 5 ledning 5 bokslutsrapport 5 egfr-testning 5 tc-5214 4 fostamatinib 4 antibiotika 4 anders ekblom 4 lungcancer 4 ledgångsreumatism 4 olaparib 4 bristol-myers squibb 4 fluenz 4 seroquel xr 4 karolinska institutet 4 osimertinib 3 crestor® 3 styrelsen 3 produkt 3 vimovo 3 slusg 3 gefitinib 3 kroniskt obstruktiv lungsjukdom 3 selumetinib 3 antibiotikaresistens 3 japan 3 egentlig depression 3 subvention 3 CVD-REAL 3 astra tech 3 pathos 3 esc 2 fulvestrant 2 confirm 2 seroquel xr (quetiapin fumarat) 2 caprelsa 2 saturn 2 klopidogrel 2 epanova 2 Brilique 2 individanpassad behandling 2 återfall 2 opioider 2 entocort 2 bydureon 2 axanum 2 astrazenca 2 life science 2 tyskland 2 benralizumab 2 recentin 2 slusg stipendium 2 byetta 2 patenttvist 2 kina 2 registerstudie 2 dapagliflozin 2 typ2diabetes 2 seroquel xl 2 corporate 2 ardea biosciences 2 Real World evidence 2 targacept 2 produktion 2 acalabrutinib 2 kvartalsrapport 2 samarbete 2 smärta 2 läkemedelsförmånen 2 mdd 2 almedalen 2 ticagrelor 2 sjukhussjuka 1 avancerad bröstcancer 1 avastin 1 kvalitetsregister 1 blodförgiftning 1 ämnesomsättningssjukdomar 1 jupiter-studien 1 ämnesomsättningssjukdomar (emdac) 1 jupiter 1 faslodex (fulvestrant) 1 monoterapi 1 den amerikanska läkemedelsmyndigheten 1 skelettmetastaser 1 roger henriksson 1 produktionsanläggning 1 ema 1 gikt 1 cardiologföreningen 1 ovarian cancer 1 merck-avtal 1 savor 1 årsredovisning 2010 1 non-executive director 1 iressa 1 nytt läkemedel mot lungcancer 1 behandling lungcancer 1 målstyrt läkemedel 1 EGFR 1 nytt läkemedel lungcancer 1 cediranib 1 bevacizumab 1 scilifelab 1 yngre forskare 1 päivi tolstoy 1 tobias ankner 1 hans andersson 1 syntetisk kemi 1 torrent pharma 1 varumärkta generika 1 saxagliptin 1 hypoglykemi 1 blodsockerkontroll 1 blodsockerfall 1 viktökning 1 ldl-c 1 gonorré 1 sepsis 1 livskvalitet lungcancer 1 ipass 1 lungcancersymtom 1 mcrc 1 complete response letter (crl) 1 u.s. food and drug administration (fda) 1 årets kvinnliga ledare 1 karin norlén 1 generiskt esomeprazolmagnesium 1 kanadensiska hälsovårdsministeriet 1 apotex inc (notice of compliance 1 noc) 1 internationell konkurrens 1 nikotinkanalsblockerare 1 läkemedel 1 DAISY 1 subventioner 1 UCR 1 zibotentan 1 vnr 1 pressmaterial 1 biokemiska markörer 1 egfr-muterad 1 cytofab 1 azd9773 1 eurika 1 kombiglyze xr 1 klinisk forsk 1 pegasus 1 produktionschef 1 AI 1 berzeliussamlingen 1 nya läkemedel 1 right honourable baroness shriti vadera 1 certriad 1 astrazeneca lund 1 arbetsmarknadsdagar 1 registreringsansökan 1 kastrationsresistent 1 fas 3-studie 1 hormonresistent 1 budesonid 1 mobil-app 1 opioidbehandling 1 nktr-118 1 sustainable brands 2011 1 forskningsportfölj 1 skatteärende 1 denosumab 1 amylin 1 patologi 1 NSCLC 1 egfr mutation 1 egfr positiv 1 komboglyze 1 caz-avi 1 hälsoekonomiska data 1 delårsrapport januari-september 2011 1 typ-1 diabetes 1 patientundersökning 1 david brennan 1 hudinfektioner 1 medicon village 1 translationell 1 illumina 1 årsredovisning 2011 1 antibiotikum 1 flumist 1 kvadrivalent 1 quetiapin fumarat 1 citizen petitions 1 renaissance 4 1 renaissance 5 1 formuleringspatent 1 citizens petition 1 hjärtkärlhälsa 1 prismodell 1 lesinurab 1 the medicines company 1 nda 1 amend 1 amylin pharmaceuticals 1 mdr-tb 1 mikael agaton 1 grymt fett 1 tonårshjärnan 1 per hamid ghatan 1 grymt fett en filmserie om tonårshjärnan 1 exacerbationer 1 pascal soriot 1 säsongsinfluensavaccin för barn som nässpray 1 säsongsinfluencavaccin 1 barninfluensavaccin 1 nässprayvaccin 1 influensanässpray 1 jonas bergh 1 bröstcancer utmärkelse 2012 1 sjukhusinfektioner 1 zinforo 1 mjukdelsinfektioner 1 ceftarolinfosamil 1 max planck institute 1 magnus björsne 1 per alfredsson 1 remissvar prismodell 1 pris läkemedel 1 strategiska centra 1 forsknings - och utvecklingscentra 1 bioläkemedel 1 tre strategiska centra 1 aks 1 exenatide 1 glp-1 agonister 1 cancerregister 1 svenska lungcancerstudiegruppen 1 non-small-cell lungcancer 1 motivationsstöd 1 patient websida 1 sekundärprevention 1 patientstöd 1 fluenz tetra 1 metreleptin 1 lipodystrofi 1 lesinurad 1 farxiga 1 xigduo 1 myalept 1 ann cairns 1 akuta koronara syndrom 1 metabola sjukdomar 1 immunoterapier 1 advaxis 1 sommarforskarskola 1 non-small cell lung cancer 1 astma/kol 1 gensekvensering 1 oic 1 hjärt-och kärlsjukdom 1 hjärinfarkt 1 biohub 1 bioventurehub 1 elisabeth björk 1 antaros 1 hha 1 healthy heart africa 1 världsdiabetesdagen 2014 1 moventig 1 Lynparza 1 opioidorsakad 1 pegasus-timi 1 e-brilique 1 Uppsala Clinical Research Center 1 mobiltelefonapplikation 1 SUPPORT-studien 1 ordnat införande Almedalen 1 QTERN 1 Zavicefta 1 moderna therapeutics 1 SvFP 1 kyntheum 1 brodalumab 1 Imfinzi 1 durvalumab 1 CVD-REAL Nordic 1 osimertinub 1 världsastmadagen 1 PACEHR 1 svår astma 1 Katarina Ageborg 1 norge 1 VD AstraZeneca Sverige AB 1 innovation 1 eu 1 blogg 1 sponsring 1 hållbar utveckling 1 patent 1 lund 1 debatt 1 forskare 1 stipendier 1 usa 1 hjärtinfarkt 1 stroke 1 kol 1 skl 1 kemi 1 influensa 1 depression 1 antidepressiva läkemedel 1 tlv 1 beslut 1 alzheimers 1 äggstockscancer 1 lif 1 prevention 1 södertälje 1 alzheimers sjukdom 1 telekonferens 1 högkostnadsskyddet 1 collaboration 1 halvårsrapport 1 forskarstipendium 1 schizofreni 1 merck 1 dow jones sustainability index 1 läkemedelsforskning 1 läkemedelstillverkning 1 pfizer 1 psoriasis 1 anläggningar 1 bakterier 1 stöd 1 karolinska universitetssjukhuset 1 kronisk smärta 1 artros 1 pa 1 delårsrapport januari - mars 1 h1n1 1 r&d 1 mölndal 1 generiska läkemedel 1 typ 2-diabetes 1 styrelseordförande 1 gener 1 apollo 1 hälsoekonomi 1 socialminister 1 halvårsresultat 1 pet 1 mrsa 1 ny indikation 1 diagnostik 1 förstoppning 1 kranskärlsjukdom 1 invasiv behandling 1 journal of clinical oncology 1 avancerad hormonkänslig bröstcancer 1 first studien 1 asco 1 konkurrenskraften 1 läkemedelsforskningen 1 forskarkarriärer 1 stipendieprogram 1 rosuvastatinkalcium 1 hyperkolesterolemi 1 pluto-studien 1 vimovotm 1 nsaid 1 pozen 1 sumitomo 1 american college of rheumatology 1 2009 annual scientific meeting in philadelphia 1 leif johansson 1 zactima (vandetanib) 1 toprol-xl 1 vaccinet 1 inflammation 1 jan lundberg 1 stemi 1 rosuvastatin 1 arimidex 1 anastrozol 1 atac 1 bypass 1 kolorektalcancer 1 Visa alla taggar

Senaste nytt

Imfinzi plus tremelimumab demonstrated promising clinical  activity and tolerability in patients with advanced liver cancer

Imfinzi plus tremelimumab demonstrated promising clinical activity and tolerability in patients with advanced liver cancer

Pressmeddelanden   •   Maj 29, 2020 14:56 CEST

Results from the global Phase II Study 22 trial testing AstraZeneca’s tremelimumab, an anti-CTLA4 antibody, added to Imfinzi (durvalumab) demonstrated promising clinical activity and tolerability in patients with advanced hepatocellular carcinoma (HCC). HCC is the most common type of liver cancer.1

Enhertu achieved a tumour response rate of 45.3% in patients with HER2-positive metastatic colorectal cancer in Phase II DESTINY-CRC01 trial

Enhertu achieved a tumour response rate of 45.3% in patients with HER2-positive metastatic colorectal cancer in Phase II DESTINY-CRC01 trial

Pressmeddelanden   •   Maj 29, 2020 14:53 CEST

Results from the Phase II DESTINY-CRC01 trial of AstraZeneca and Daiichi Sankyo Company, Limited (Daiichi Sankyo)’s Enhertu (trastuzumab deruxtecan) demonstrated clinically meaningful activity in patients with HER2-positive unresectable and/or metastatic colorectal cancer who received at least two prior lines of standard treatment.

Enhertu demonstrated meaningful clinical activity in patients with HER2-mutant non-small cell lung cancer in interim analysis of Phase II  DESTINY-Lung01 trial

Enhertu demonstrated meaningful clinical activity in patients with HER2-mutant non-small cell lung cancer in interim analysis of Phase II DESTINY-Lung01 trial

Pressmeddelanden   •   Maj 29, 2020 14:42 CEST

Results from the ongoing Phase II DESTINY-Lung01 trial showed AstraZeneca and Daiichi Sankyo Company, Limited (Daiichi Sankyo)’s Enhertu (trastuzumab deruxtecan) achieved a clinically meaningful tumour response in patients with HER2-mutant (HER2m) unresectable and/or metastatic non-squamous non-small cell lung cancer (NSCLC) whose disease had progressed following one or more systemic therapies.

Enhertu significantly improved tumour response rate and overall survival in HER2-positive metastatic gastric cancer in Phase II DESTINY-Gastric01 trial

Enhertu significantly improved tumour response rate and overall survival in HER2-positive metastatic gastric cancer in Phase II DESTINY-Gastric01 trial

Pressmeddelanden   •   Maj 29, 2020 14:09 CEST

Detailed results from the positive, registrational, randomised controlled Phase II DESTINY-Gastric01 trial showed AstraZeneca and Daiichi Sankyo Company, Limited (Daiichi Sankyo)’s Enhertu (trastuzumab deruxtecan) demonstrated a statistically significant and clinically meaningful improvement in objective response rate (ORR) and overall survival (OS), a key secondary endpoint, versus chemotherapy.

Imfinzi showed a sustained overall survival benefit in 1st-line  extensive-stage small cell lung cancer in the Phase III CASPIAN trial

Imfinzi showed a sustained overall survival benefit in 1st-line extensive-stage small cell lung cancer in the Phase III CASPIAN trial

Pressmeddelanden   •   Maj 29, 2020 14:03 CEST

Detailed results from an updated analysis of the Phase III CASPIAN trial showed AstraZeneca’s Imfinzi (durvalumab) in combination with a choice of chemotherapies, etoposide plus either carboplatin or cisplatin, demonstrated a sustained, clinically meaningful overall survival (OS) benefit for adults with extensive-stage small cell lung cancer (ES-SCLC) treated in the 1st-line setting.

Tagrisso demonstrated unprecedented disease-free survival in the adjuvant treatment of Stage IB-IIIA patients with EGFR-mutated lung cancer

Tagrisso demonstrated unprecedented disease-free survival in the adjuvant treatment of Stage IB-IIIA patients with EGFR-mutated lung cancer

Pressmeddelanden   •   Maj 28, 2020 23:03 CEST

Detailed results from the Phase III ADAURA trial showed AstraZeneca’s Tagrisso (osimertinib) demonstrated a statistically significant and clinically meaningful improvement in disease-free survival (DFS) in the adjuvant treatment of patients with early-stage (IB, II and IIIA) epidermal growth factor receptor-mutated (EGFRm) non-small cell lung cancer (NSCLC) ......

AstraZeneca collaborates with ArcherDX to use personalised cancer assays  to detect minimal residual disease in lung cancer trials
Enhertu granted Orphan Drug Designation in the US for gastric cancer

Enhertu granted Orphan Drug Designation in the US for gastric cancer

Pressmeddelanden   •   Maj 22, 2020 08:09 CEST

AstraZeneca and Daiichi Sankyo Company, Limited (Daiichi Sankyo)’s Enhertu (trastuzumab deruxtecan) has been granted Orphan Drug Designation (ODD) in the US for the treatment of patients with gastric cancer, including gastroesophageal junction cancer.

AstraZeneca advances response to global COVID-19 challenge as it receives first commitments for Oxford’s potential new vaccine

AstraZeneca advances response to global COVID-19 challenge as it receives first commitments for Oxford’s potential new vaccine

Pressmeddelanden   •   Maj 21, 2020 08:16 CEST

AstraZeneca is advancing its ongoing response to address the unprecedented challenges of COVID-19, collaborating with a number of countries and multilateral organisations to make the University of Oxford’s vaccine widely accessible around the world in an equitable manner.

Lynparza approved in the US for HRR gene-mutated metastatic castration-resistant prostate cancer

Lynparza approved in the US for HRR gene-mutated metastatic castration-resistant prostate cancer

Pressmeddelanden   •   Maj 20, 2020 08:48 CEST

AstraZeneca and MSD Inc., Kenilworth, N.J., US (MSD: known as Merck & Co., Inc. inside the US and Canada) today announced that Lynparza (olaparib) has been approved in the US for patients with homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC).

Enhertu granted Breakthrough Therapy Designation in the US for HER2-mutant metastatic non-small cell lung cancer

Enhertu granted Breakthrough Therapy Designation in the US for HER2-mutant metastatic non-small cell lung cancer

Pressmeddelanden   •   Maj 18, 2020 09:12 CEST

AstraZeneca and Daiichi Sankyo Company, Limited (Daiichi Sankyo)’s Enhertu (trastuzumab deruxtecan) has been granted Breakthrough Therapy Designation (BTD) in the US for the treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumours have a HER2 mutation and with disease progression on or after platinum-based therapy.

Bevespi Aerosphere approved in China for patients with COPD

Bevespi Aerosphere approved in China for patients with COPD

Pressmeddelanden   •   Maj 18, 2020 08:49 CEST

AstraZeneca’s Bevespi Aerosphere (glycopyrronium/formoterol fumarate) has been approved in China as a maintenance treatment to relieve symptoms in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and/or emphysema.

AstraZeneca advances the science of cancer medicine with practice-changing data at the ASCO20 Virtual Scientific Program

AstraZeneca advances the science of cancer medicine with practice-changing data at the ASCO20 Virtual Scientific Program

Pressmeddelanden   •   Maj 13, 2020 23:02 CEST

AstraZeneca will present ground-breaking new results across its broad portfolio of cancer medicines during the 2020 American Society of Clinical Oncology ASCO20 Virtual Scientific Program, 29 to 31 May 2020. AstraZeneca will present 98 abstracts, including 19 oral presentations with one plenary and 10 late-breakers.

Enhertu granted Breakthrough Therapy Designation in the US for HER2-positive metastatic gastric cancer

Enhertu granted Breakthrough Therapy Designation in the US for HER2-positive metastatic gastric cancer

Pressmeddelanden   •   Maj 11, 2020 08:04 CEST

AstraZeneca and Daiichi Sankyo Company, Limited (Daiichi Sankyo)’s Enhertu (trastuzumab deruxtecan) has been granted Breakthrough Therapy Designation (BTD) in the US for the treatment of patients with HER2-positive unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma who have received two or more prior regimens including trastuzumab.

AstraZeneca recovery of global rights to brazikumab (MEDI2070) from Allergan completed

AstraZeneca recovery of global rights to brazikumab (MEDI2070) from Allergan completed

Pressmeddelanden   •   Maj 11, 2020 08:02 CEST

​AstraZeneca has completed a previously communicated agreement to recover the global rights to brazikumab (formerly MEDI2070), a monoclonal antibody targeting IL23, from Allergan. AstraZeneca and Allergan have terminated their previous license agreement and all rights to brazikumab have therefore now returned to AstraZeneca.

Lynparza approved in the US as 1st-line maintenance treatment with bevacizumab for HRD-positive advanced ovarian cancer

Lynparza approved in the US as 1st-line maintenance treatment with bevacizumab for HRD-positive advanced ovarian cancer

Pressmeddelanden   •   Maj 11, 2020 08:01 CEST

AstraZeneca and MSD Inc., Kenilworth, N.J., US today announced that Lynparza (olaparib) in combination with bevacizumab has been approved in the US for the maintenance treatment of adult patients with advanced epithelial ovarian, fallopian tube or primary peritoneal cancer.

Farxiga approved in the US for the treatment of heart failure  in patients with heart failure with reduced ejection fraction

Farxiga approved in the US for the treatment of heart failure in patients with heart failure with reduced ejection fraction

Pressmeddelanden   •   Maj 06, 2020 08:02 CEST

​AstraZeneca’s Farxiga (dapagliflozin) has been approved in the US to reduce the risk of cardiovascular (CV) death and hospitalisation for heart failure in adults with heart failure (NYHA class II-IV) with reduced ejection fraction (HFrEF) with and without type-2 diabetes (T2D).

AstraZeneca and Oxford University announce  landmark agreement for COVID-19 vaccine

AstraZeneca and Oxford University announce landmark agreement for COVID-19 vaccine

Pressmeddelanden   •   Apr 30, 2020 08:18 CEST

AstraZeneca and the University of Oxford today announced an agreement for the global development and distribution of the University’s potential recombinant adenovirus vaccine aimed at preventing COVID-19 infection from SARS-CoV-2.

AstraZeneca PLC:s resultatrapport för första kvartalet 2020

AstraZeneca PLC:s resultatrapport för första kvartalet 2020

Pressmeddelanden   •   Apr 29, 2020 08:20 CEST

Stabilt resultat i en tid som saknar motstycke; lyfter vikten av den vetenskapliga expertisen i kampen mot COVID-19

Lynparza demonstrated overall survival benefit in Phase III PROfound trial for BRCA1/2 or ATM-mutated metastatic castration-resistant prostate cancer

Lynparza demonstrated overall survival benefit in Phase III PROfound trial for BRCA1/2 or ATM-mutated metastatic castration-resistant prostate cancer

Pressmeddelanden   •   Apr 24, 2020 08:01 CEST

AstraZeneca and MSD Inc., Kenilworth, N.J., US today announced further positive results from the Phase III PROfound trial of Lynparza (olaparib) in men with metastatic castration-resistant prostate cancer (mCRPC) who have a homologous recombination repair gene mutation (HRRm) and have progressed on prior treatment with new hormonal agent (NHA) treatments (e.g. enzalutamide and abiraterone).